Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Hims & Hers’

The typical tech leader’s pay rose $810k since 2021—more than COOs, CFOs, and CIOs combined

Median compensation for tech executives rose 45% from 2021 to 2025, faster than it did for CEOs, CFOs, and COOs.

MarketBeat Week in Review – 08/24 - 08/28

MarketBeat Week in Review – 08/24 - 08/28

MarketBeat analysts recap a mixed earnings week, covering AI infrastructure demand, retail's K-shaped consumer trends, Meta's $18 billion settlement, and stock picks across tech, biotech, and retail sectors.

Hims & Hers’ Revenue Beat Came With a Profitability Problem

Hims & Hers’ Revenue Beat Came With a Profitability Problem

Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic

Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook ahead of Q2 earnings.

Bearish Pressure Is Building Around These 3 Stocks

Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.

HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business Practices

Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.

HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the news means for HIMS stock.

inkl

Read news from The Economist, FT, and more,
with one subscription

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

FDA to discuss easing restrictions on peptides despite safety concerns

FDA to discuss easing restrictions on peptides despite safety concerns

Committee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacy

The Guardian - US

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

The Silver Lining of Last Week's Hims & Hers Earnings Miss

The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

Hims & Hers Health Q1 Earnings Call Highlights

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to know

Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to know

Hims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and revenue below expectations. Despite these weak results, the company raised its full-year revenue outlook and projected strong second-quarter revenue, as it navigates regulatory scrutiny around weight-loss drugs.

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

Should You Buy HIMS Stock Following Friday's Rally?

Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.

International Business Times

Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum

Shares of Hims & Hers Health Inc. climbed sharply in morning trading Friday as investors bet that potential regulatory relief on compounded peptides could strengthen the telehealth company's weight-loss offerings and broader platform growth.

RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?

Hims & Hers stock rallies as RFK Jr. says FDA may remove restrictions on certain peptides. But HIMS shares remain unattractive to own in 2026.

Hims and Hers reveal cyberattack — customer support system hacked and personal info stolen, here's what we know

At least 500 people were affected in breach at Hims and Hers.

Get all your
news in one place.

100's of premium titles.
One news app.

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

International Business Times

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!

The Independent UK

Novo Nordisk drops lawsuit over weight loss medications, enters collaboration with online pharmacy

The news sent shares of Hims & Hers Health Inc. soaring by more than 40% in Monday morning trading

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.

1 2 3 4

People

Robert F. Kennedy Jr

Jeffrey Neal Johnson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

418,834 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play